




Euda Health

CORPORATE PRESENTATION 2025



Confidentiality and Disclaimer

This confidential presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the “proposed business combination”) between Euda Health Limited (“EUDA”) and 8i Acquisition 2 Corp (“8i” or the “SPAC”) and related transactions and for no other purpose. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute financial investment, tax or legal advice. To the fullest extent permitted by law in no circumstances will EUDA, 8i or any of their respective subsidiaries, shareholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this presentation, its contents, its omissions, errors, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. No representations or warranties, express or implied, is or will be given by EUDA, 8i or any of their respective affiliates, directors, officers, employees or advisors or any other person as to the accuracy, completeness, reasonableness of statements, estimates, targets, projections, assumptions or judgments in this presentation, or in any other written, oral or other communications transmitted otherwise made available to any part in the course of its evaluation of a possible transaction, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. Industry and market data used in this presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither EUDA nor 8i has independently verified the data obtained from these sources and cannot assure you of the accuracy or completeness of the data. In addition, this presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of EUDA or the proposed business combination. Viewers of this presentation should each make their own evaluation of EUDA and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. EUDA and 8i disclaim any duty to update the information contained in this presentation.

The information in this presentation is highly confidential. The distribution of this presentation by an authorized recipient to any other person is unauthorized. Any photocopying, disclosure, reproduction or alteration of the contents of this presentation and any forwarding of a copy of this presentation or any portion of this presentation to any person is prohibited. The recipient of this presentation shall keep this presentation and its contents confidential, shall not use this presentation and its contents for any purpose other than as expressly authorized by EUDA and 8i and shall be required to return or destroy all copies of this presentation or portions thereof in its possession promptly following request for the return or destruction of such copies. By accepting delivery of this presentation, the recipient is deemed to agree to the foregoing confidentiality requirements. This presentation contains trademarks, service marks, trade names and copyrights of EUDA, 8i and other companies, which are the property of their respective owners.

Forward-looking Statements

This document includes certain statements, estimates, targets, forward-looking statements, and projections (collectively, “forward-looking statements”) that reflect assumptions made by EUDA concerning anticipated future performance of EUDA and its industry. Such forward-looking statements are based on significant assumptions and subjective judgments concerning anticipated results, which are inherently subject to risks, variability, and contingencies, many of which are beyond EUDA’s control. Factors that could cause actual results to differ from these forward-looking statement include, but are not limited to, general economic conditions, the availability and terms of financing, the effects and uncertainties created by the ongoing COVID-19 pandemic, EUDA’s limited operating history, changes in regulatory requirements and governmental incentives, competition, and other risks and uncertainties associated with EUDA’s research and development activities and commercial production and sales. Such forward-looking statements may be identified by the use of words like “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “seek” and similar expressions and include any financial projections or estimates or pro forma financial information set forth herein. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. EUDA shall not undertake any duty to update these forward-looking statements, or the other information contained in this presentation. EUDA do not make any representation or warranty, express or implied, as to the accuracy or completeness of this document or any other information (whether written or oral) that has been or will be provided to you. Nothing contained herein or in any other oral or written information provided to you is, nor shall be relied upon as, a promise or representation of any kind by EUDA. Without limitation of the foregoing, EUDA expressly disclaims any representation regarding any projections concerning future operating results or any other forward-looking statement contained herein or that otherwise has been or will be provided to you. EUDA shall not be liable to you or any prospective investor or any other person for any information contained herein or that otherwise has been or will be provided to you, or any action heretofore or hereafter taken or omitted to be taken, in connection with this potential transaction. These forward-looking statements also involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted in connection with any proposed business combination; (2) the inability to complete any business combination; (3) delays in obtaining, or inability to obtain necessary regulatory approvals or complete regulatory reviews required to complete any business combination; (4) the risk that any proposed business combination disrupts current plans and operations; (5) the inability to recognize the anticipated benefits or any propose business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and partners and retain key employees; (6) costs related to any proposed business combination; (7) changes in the applicable laws or regulations; (8) the possibility that EUDA or the Combined Company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of the global COVID-19 pandemic; (10) other risks and uncertainties separately provided to the recipient and indicated from time to time described in 8i’s filings and future filings by EUDA, 8i and the Combined Company with the U.S. Securities and Exchange Commission. EUDA and 8i caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. EUDA and 8i undertake no obligation to and accepts no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

No Offer Or Solicitation: This communication does not constitute an offer to sell or a solicitation of an offer to buy, or the solicitation of any vote or approval in any jurisdiction in connection with the Proposed Investment or any related transactions, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful.

Private Placement: The securities to which this presentation relates have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction. This presentation relates to securities that EUDA would intend to offer in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securities authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense.

Forward-looking Statements

Use of Projections: This presentation contains projected financial information with respect to EUDA. Such projected financial information contains forward-looking information and is for illustration purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecasts information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties. See “Forward-Looking Statements” above. Actual results may differ materially from the results contemplated by the financial forecast information contained in the presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved.

Financial Information; Non-GAAP Financial Terms: The financial information and data contained in this presentation is unaudited and does not conform to Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any proxy statement or registration statement or other report or document to be filed by 8i with the SEC. Furthermore, some of the projected financial information and data contained in this presentation, such as adjusted EBITDA (and related measures), has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). 8i and EUDA believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to EUDA’ financial condition and results of operations. EUDA’ management uses these non-GAAP measures for trends analyses and for budgeting and planning purposes. 8i and EUDA believe that use of these non-GAAP measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing EUDA’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management of EUDA does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in EUDA’ financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures. You should review EUDA’s audited financial statements, which will be presented in 8i’s proxy statement to be filed with the SEC, and not rely on any single financial measure to evaluate EUDA’s business. A reconciliation of non-GAAP financial measures in the presentation to the most directly comparable GAAP financial measures is not included because, without unreasonable effort, EUDA is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate these non-GAAP financial measures.

Trademarks: This presentation contains trademarks, trade names and copyrights of EUDA, 8i and other companies, which are the property of their respective owners.

Additional Information and Where to Find it: This document relates to a proposed transaction between 8i and EUDA. 8i intends to file a proxy statement which will be sent to all 8i shareholders. 8i also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of 8i and EUDA are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by 8i through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by 8i may be obtained free of charge from 8i’s website at www.8iac.com or by written request to 8i at 6 Eu Tong Sen Street, #08-13 Singapore 059817.

Participants in Solicitation: 8i and EUDA and their respective directors and officers may be deemed to be participants in the solicitation of proxies from 8i’s shareholders in connection with the proposed transaction. Information about 8i’s directors and executive officers and their ownership of 8i’s securities is set forth in 8i’s filings with the SEC, including 8i’s Registration Statement on Form S-1, which was filed with the SEC on November 9, 2021. To the extent that holdings of 8i’s securities have changed since the amounts printed on 8i’s Registration Statement on Form S-1, such changes will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of these persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.



The Future of Health & Medical Care:

EXCLUSIVE INVESTMENT OPPORTUNITIES IN ASIA'S HEALTHCARE AND MEDICAL CARE GIANTS



Key Businesses

EUDA HELIXÉ




Bioenergy Capsule



Stem Cell –
Immunotherapy &
Stem Cell Treatment



CRISPR – Gene
Editing



EUDA HELIXÉ

Euda Helixé - Precision Nutrigenomic Supplement



- Developed by: Prof. Lim (“Father of Molecular Placenta & Bird’s Nest”), with 80+ patents.
- Previously Riway, sold 1 million bottles annually. Current formulation stronger.
- Benefits: Euda Helixé is a key that unlocks your body’s longevity potential by activating youth-enhancing genes and silencing those linked to aging, inflammation, and cellular decline.
- Core ingredients: Molecular deer placenta and bioactive antioxidant compounds
- Formulated in GMP-certified lab, ingredients sourced from New Zealand.
- Exclusive distributorship worldwide

Bioenergy Capsule

Bioenergy Capsule (Singapore, Malaysia, China)

- Non-invasive bio resonance infrared capsule that promotes detox, recovery, circulation, metabolism.
- Geographic rollout: Singapore (EHPL), Malaysia (via CK Health), China (Keylock)
- Vision: Asia's leading bio resonance capsule integrated into longevity and wellness Centers.





Stem Cell Treatment


Joint Venture with Guangdong Cell Biotech

- 37 centers across China, Indonesia and Cambodia
- Business model: Refer regional clients (Singapore, Malaysia) to China for treatment.
- Established since 1999 Shandong Red Cross Interventional hospital for Stem Cell application, commercialized later on
- Founder Dr Wang Tai Hua, previously Oncologist specialize Lung Cancer

Stem Cell Immunotherapy

Distribution of TCEL Immunotherapy

- Distribution rights in Asia via Shenzhen Inno Immune Co. Ltd.
- Applications: Tumor targeting, immune enhancement, personalized cellular therapy.
- Affordable TCEL Therapy compared to western alternatives
- Manufacturing: Backed by Sequoia Capital, GMP-certified, elite "Peacock Plan" R&D accreditation.



STEM CELL (IPSC)

GO POSB Organoids (IPSC Platform)

- Founded by Prof. Lim Kah Meng, former senior A*STAR scientist.
- A*STAR (Agency for Science, Technology and Research) is Singapore's top government-backed research agency.
- Many of Singapore's top scientists and biotech companies come from A*STAR labs.
- Partnering with A*STAR means shaping national science policy, develop tech for global impact.
- Collaboration with A*Star to develop Patented IPSC platform.
- Production of clinical grade hiPSC's from adult tissue.
- Received third party GMP-certified lab.
- Genetically diverse IPSC banks tailored for Asian populations.
- IP portfolio and strong scientific publication base.



IPSC the Crown Jewel of regenerative medicine

- IPSCs are adult cells reprogrammed to become any cell type in the body
- Offer regenerative power like embryonic stem cells without ethical issues
- Enable personalized, scalable, and clinically advanced therapies

What Euda is doing with IPSC

- EUDA signed LOI with GO POSB, gaining access to advanced iPSC platform
- Developing a state-of-the-art iPSC lab in Shenzhen for clinical production and distribution
- Forming strategic research alliance with A*STAR Singapore for scientific and clinical validation





Wuhan Kane Hospital

Clinical Deployment Anchor in China

- 12,000 sqm, luxury 5-star regenerative hospital in Wuhan.
- Comprehensive medically licensed general hospital with proper medical license for clinical trials and treatment using advanced IPSC solution
- Partnering with Prof. Lim patented A*Star IPSC platform to launch cell therapy R&D lab onsite.
- This partnership will be announced through press releases handled by expert team of Investor relations
- Legal platform to treat Chinese customer and patients

Future iPSC treatments

Clinical-Grade Use Cases

iPSC technology unlocks new frontiers in personalized and preventive healthcare. EUDA's pipeline includes:

- Anti-aging therapies through hormone and immune restoration
- Islet cell regeneration for diabetes management
- Cartilage and joint repair for pain and mobility
- iPSC-based skin and hair rejuvenation for the aesthetic market
- Immune system enhancement for chronic illness prevention

All delivered through licensed clinical centers like Wuhan Kaien Hospital, which offers a five-star environment and regulatory compliance for advanced therapies



CRISPR – GENE EDITING

CRISPR Platform by Prof. Zhu Jian Kang

- Prof. Zhu Jian Kang, Ranked #1 life sciences scientist in the world
- Clinical trials at Southern University of Science and Technology–King's College London, School of Medicine
- Proprietary CRISPR-based gene silencing technology.
- Functional cure for all three diseases, target 2027
 - Cure Thalassemia
 - Eradicate HIV
 - Reverse Hyperlipidemia
- Precision gene excision to permanently eliminate the root genetic cause of disease with less off targets for safety and at an affordable price.





We are shaping the next chapter of healthcare, where validated science meets real-world delivery, and long-term value is built on innovation, access, and trust.



THANK YOU